ABSTRACT
Importance With the emergence of more transmissible SARS-CoV-2 variants of concern (VOC), there is an urgent need for evidence about disease severity and the health care impacts of VOC in North America, particularly since a substantial proportion of the population have declined vaccination thus far.
Objective To examine 30-day outcomes in Canadians infected with SARS-CoV-2 in the first year of the pandemic and to compare event rates in those with VOC versus wild-type infection.
Design Retrospective cohort study using linked healthcare administrative datasets.
Setting Alberta and Ontario, the two Canadian provinces that experienced the largest third wave in the spring of 2021.
Participants All individuals with a positive SARS-CoV-2 reverse transcriptase polymerase chain reaction swab from March 1, 2020 until March 31, 2021, with genomic confirmation of VOC screen-positive tests during February and March 2021 (wave 3).
Exposure of Interest VOC versus wild type SARS-CoV-2
Main Outcomes and Measures All-cause hospitalizations or death within 30 days after a positive SARS-CoV-2 swab.
Results Compared to the 372,741 individuals with SARS-CoV-2 infection between March 2020 and January 2021 (waves 1 and 2 in Canada), there was a shift in transmission towards younger patients in the 104,232 COVID-19 cases identified in wave 3. As a result, although third wave patients were more likely to be hospitalized (aOR 1.34 [1.29-1.39] in Ontario and aOR 1.53 [95%CI 1.41-1.65] in Alberta), they had shorter lengths of stay (median 5 vs. 7 days, p<0.001) and were less likely to die within 30 days (aOR 0.66 [0.60-0.71] in Ontario and aOR 0.74 [0.62-0.89] in Alberta). However, within the third wave, patients infected with VOC (91% Alpha) exhibited higher risks of death (aOR 1.52 [1.27-1.81] in Ontario and aOR 1.67 [1.13-2.48] in Alberta) and hospitalization (aOR 1.57 [1.47-1.69] in Ontario and aOR 1.88 [1.74-2.02] in Alberta) than those with wild-type SARS-CoV-2 infections during the same timeframe.
Conclusions and Relevance On a population basis, the shift towards younger age groups as the COVID-19 pandemic has evolved translates into more hospitalizations but shorter lengths of stay and lower mortality risk than seen in the first 10 months of the pandemic in Canada. However, on an individual basis, infection with a VOC is associated with a higher risk of hospitalization or death than the original wild-type SARS-CoV-2 – this is important information to address vaccine hesitancy given the increasing frequency of VOC infections now.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CIHR COVID-19 Rapid Research Funding Opportunity grant (# VR4 172736) No payment to authors or their institutions for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was granted by the University of Alberta Health Ethics Research Board (Pro00101096) with waiver of individual patient signed informed consent for Alberta data as we analyzed deidentified healthcare administrative data within the secure environment of the Alberta Strategy for Patient Oriented Research Support Unit. The use of Ontario data is authorized under section 45 of Ontarios Personal Health Information Protection Act (PHIPA) and does not require review by another Research Ethics Board as it was analyzed within the secure environment of the Institute for Clinical Evaluative Sciences (ICES) which is a prescribed entity (ie. health information custodian) under the PHIPA. As a prescribed entity ICES undergoes tri-annual review and approval of its privacy and security policies procedures and practices by Ontarios Information and Privacy Commissioner. In addition each research project that is conducted at ICES (including this one) is also subject to internal ethical review by the ICES Privacy and Compliance Office.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Supported by: CIHR COVID-19 Rapid Research Funding Opportunity grant (# VR4 172736)
Disclosures: FAM holds the Alberta Health Services Chair in Cardiovascular Outcomes Research, DSL is the Ted Rogers Chair in Heart Function Outcomes, University Health Network, University of Toronto. None of the authors have any competing interests to declare.
Data Availability
To comply with each province Health Information Protection Act the dataset used for this study cannot be made publicly available but requests to access the dataset from qualified researchers trained in human subject confidentiality protocols may be sent to the corresponding author.
